Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic Tools for Hypersensitivity to Platinum Drugs and Taxanes: Skin Testing, Specific IgE, and Mast Cell/Basophil Mediators

  • ANAPHYLAXIS AND DRUG ALLERGY (DA KHAN AND M CASTELLS, SECTION EDITORS)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Hypersensitivity reactions (HSRs) to platinum drugs and taxanes are increasing in cancer patients, and rapid drug desensitization has emerged as a safe and effective method to reintroduce these drugs in reactive patients. Optimal management of patients presenting HSRs to chemotherapy depends on the use of various diagnostic tools, which include measurement of mast cell/basophil mediator release following a HSR and skin testing. Serum tryptase should be measured in patients presenting chemotherapy HSRs, and its elevation would support mast cell/basophil activation. Skin testing to platinum drugs has a high sensitivity and specificity and is critical to guide the management of platinum-reactive patients. Taxane skin testing is also emerging as a useful diagnostic and risk stratification tool in the evaluation of patients with HSRs to taxanes. Platinum sIgE assays have been recently developed and can be helpful in combination with skin testing or as an alternative when skin testing is not available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Mezzano V, Giavina-Bianchi P, Picard M, Caiado J, Castells M. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs. 2014;28(2):133–44.

    CAS  PubMed  Google Scholar 

  2. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574–80.

    CAS  PubMed  Google Scholar 

  3. Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol. 2012;129(2):443–7. Risk stratification of patients with carboplatin-induced hypersensitivity reaction trough clinical presentation and skin testing.

    CAS  PubMed  Google Scholar 

  4. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy. 2013;68(7):853–61. Outcomes of a desensitization to chemotherapeutics in a large cohort of patients; assessment of the value of oxaliplatin-specific IgE.

    CAS  PubMed  Google Scholar 

  5. Chatelut E. Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability. Bull Cancer. 2011;98(11):1253–61.

    CAS  PubMed  Google Scholar 

  6. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(30):3752–63.

    Google Scholar 

  7. Geiger JL, Lazim AF, Walsh FJ, Foote RL, Moore EJ, Okuno SH, et al. Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma. Oral Oncol. 2014;50(4):311–8.

  8. Sakaeda T, Kadoyama K, Okuno Y. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci. 2011;8(6):487–91.

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(3):300–7.

    CAS  Google Scholar 

  10. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.

    CAS  PubMed  Google Scholar 

  11. Navo M, Kunthur A, Badell ML, Coffer 2nd LW, Markman M, Brown J, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol. 2006;103(2):608–13.

    CAS  PubMed  Google Scholar 

  12. Liu A, Fanning L, Chong H, Fernandez J, Sloane D, Sancho-Serra M, et al. Desensitization regimens for drug allergy: state of the art in the 21st century. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2011;41(12):1679–89.

    CAS  Google Scholar 

  13. Koren C, Yerushalmi R, Katz A, Malik H, Sulkes A, Fenig E. Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol. 2002;25(6):625–6.

    PubMed  Google Scholar 

  14. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Metal-Based Drugs. 2010;2010.

  15. Park SJ, Lee KY, Park WS, Min SY. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions. Oncology. 2013;85(6):323–7.

    CAS  PubMed  Google Scholar 

  16. Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol. 2014;15:1.

    PubMed Central  PubMed  Google Scholar 

  17. Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology. 2009;76(1):36–41.

    CAS  PubMed  Google Scholar 

  18. Kim MY, Kang SY, Lee SY, Yang MS, Kim MH, Song WJ, et al. Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans. Asian Pac J Cancer Prev APJCP. 2012;13(4):1209–15.

    Google Scholar 

  19. Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology. 2009;76(4):231–8.

    CAS  PubMed  Google Scholar 

  20. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.

    CAS  PubMed  Google Scholar 

  21. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(4):1141.

    CAS  Google Scholar 

  22. Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(12):3126–9.

    CAS  Google Scholar 

  23. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(24):4611–4.

    CAS  Google Scholar 

  24. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004;95(2):370–6.

    CAS  PubMed  Google Scholar 

  25. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99(2):393–9.

    PubMed  Google Scholar 

  26. Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer. 2005;104(3):640–3.

    CAS  PubMed  Google Scholar 

  27. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009;123(6):1262–7 e1.

    CAS  PubMed  Google Scholar 

  28. Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2003;14(3):497–8.

    CAS  Google Scholar 

  29. Herrero T, Tornero P, Infante S, Fuentes V, Sanchez MN, De Barrio M, et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol. 2006;16(5):327–30.

    CAS  PubMed  Google Scholar 

  30. Pagani M, Bonadonna P, Senna GE, Antico A. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol. 2008;145(1):54–7.

    CAS  PubMed  Google Scholar 

  31. Pagani M, Bonadonna P. Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin. Anticancer Res. 2014;34(1):537–40.

    CAS  PubMed  Google Scholar 

  32. Wong JT, Ling M, Patil S, Banerji A, Long A. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract. 2014;2(1):40–5.

    PubMed  Google Scholar 

  33. Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol. 2007;119(3):726–30.

    CAS  PubMed  Google Scholar 

  34. Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract. 2013;1(5):494–500. Assessment of the value of platinum-specific IgE in the diagnosis and evaluating the cross-reactivity between different platinum drugs in 24 patients and 17 controls.

    PubMed  Google Scholar 

  35. Pagani M, Venemalm L, Bonnadona P, Vescovi PP, Botelho C, Cernadas JR. An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem. Jpn J Clin Oncol. 2012;42(4):347–50.

    PubMed  Google Scholar 

  36. Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer. 1998;34(8):1297–8.

    CAS  PubMed  Google Scholar 

  37. Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL. Anaphylaxis after oxaliplatin. Ann Oncol Off J Eur Soc Med Oncol ESMO. 1999;10(5):610.

    CAS  Google Scholar 

  38. Wang JH, King TM, Chang MC, Hsu CW. Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol WJG. 2012;18(38):5427–33.

    CAS  Google Scholar 

  39. Gastaminza G, de la Borbolla JM, Goikoetxea MJ, Escudero R, Anton J, Espinos J, et al. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol. 2011;21(2):108–12.

    CAS  PubMed  Google Scholar 

  40. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Guillen-Ponce C, Sanz ML, Alvarez-Cuesta E. Desensitizing oxaliplatin-induced fever: a case report. J Investig Allergol Clin Immunol. 2013;23(6):435–6.

    CAS  PubMed  Google Scholar 

  41. Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2001;12(1):132–3.

    CAS  Google Scholar 

  42. Ulrich-Pur H, Penz M, Fiebiger WC, Schull B, Kornek GV, Scheithauer W, et al. Oxaliplatin-induced fever and release of IL-6. Oncology. 2000;59(3):187–9.

    CAS  PubMed  Google Scholar 

  43. Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S126–37.

    PubMed  Google Scholar 

  44. Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital. Gynecol Oncol. 2007;105(1):81–3.

    CAS  PubMed  Google Scholar 

  45. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2005;15(1):13–8.

    CAS  Google Scholar 

  46. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2008;18(4):615–20.

    CAS  Google Scholar 

  47. Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer. 2013;109(4):1072–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  48. Maindrault-Goebel F, Andre T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer. 2005;41(15):2262–7.

    CAS  PubMed  Google Scholar 

  49. Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2006;17(2):259–61.

    CAS  Google Scholar 

  50. Picard M, Matulonis UA, Castells M. Chemotherapy hypersensitivity reactions in ovarian cancer. J Natl Compr Cancer Netw. 2014;12(3):389–402.

    CAS  Google Scholar 

  51. Taxol prescribing information 2014 [January 13, 2014]. Available from: http://packageinserts.bms.com/pi/pi_taxol.pdf.

  52. Taxotere prescribing information 2013 [December 24, 2013]. Available from: http://products.sanofi.us/Taxotere/taxotere.html.

  53. Abraxane prescribing information 2014 [January 3, 2014]. Available from: http://abraxane.com/downloads/Abraxane_PrescribingInformation.pdf.

  54. Cabazitaxel prescribing information 2014 [January 12, 2014]. Available from: http://products.sanofi.us/jevtana/jevtana.html.

  55. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–8.

    CAS  PubMed  Google Scholar 

  56. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18(1):102–5.

    CAS  PubMed  Google Scholar 

  57. A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. Allergy Asthma Proc. 2011;32(1):79.

  58. Picard M, Pur L, Caiado J, Galvao V, Giavina-Bianchi P, Castells M. Added value of skin testing in hypersensitivity reactions to taxanes [Abstract]. J Allergy Clin Immunol. 2014;133(2):AB152.

    Google Scholar 

  59. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325–7.

    CAS  PubMed  Google Scholar 

  60. Exposito O, Bonfill M, Moyano E, Onrubia M, Mirjalili MH, Cusido RM, et al. Biotechnological production of taxol and related taxoids: current state and prospects. Anticancer Agents Med Chem. 2009;9(1):109–21.

    CAS  PubMed  Google Scholar 

  61. Gennari A, Salvadori B, Tognoni A, Conte PF. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol. 1996;7(9):978–9.

    CAS  PubMed  Google Scholar 

  62. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol. 1997;8(6):611–4.

    CAS  PubMed  Google Scholar 

  63. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol. 1997;15(12):3517.

    CAS  PubMed  Google Scholar 

  64. Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol. 2002;84(3):420–5.

    CAS  PubMed  Google Scholar 

  65. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654–66.

    CAS  PubMed  Google Scholar 

  66. Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV. Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol. 1998;69(2):122–4.

    CAS  PubMed  Google Scholar 

  67. Cormio G, Di Vagno G, Melilli GA, Cazzolla A, Di Gesu G, Carriero C, et al. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother. 1999;11(5):407–9.

    CAS  PubMed  Google Scholar 

  68. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol. 1993;4(7):610–1.

    CAS  PubMed  Google Scholar 

  69. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994;12(6):1232–7.

    CAS  PubMed  Google Scholar 

  70. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998;16(10):3426–32.

    CAS  PubMed  Google Scholar 

  71. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643–55.

    CAS  PubMed  Google Scholar 

  72. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682–91.

    CAS  PubMed  Google Scholar 

  73. Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol. 2011;156(3):320–4.

    CAS  PubMed  Google Scholar 

  74. Ma P, Mumper RJ. Paclitaxel nano-delivery systems: a comprehensive review. J Nanomedicine Nanotechnol. 2013;4(2):1000164.

    Google Scholar 

  75. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803.

    CAS  PubMed  Google Scholar 

  76. Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther. 2011;4:123–36.

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown 3rd JV. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol. 2006;100(2):437–8.

    CAS  PubMed  Google Scholar 

  78. Fader AN, Rose PG. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer. 2009;19(7):1281–3.

    PubMed  Google Scholar 

  79. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug Discov. 2010;9(9):677–8.

    CAS  PubMed  Google Scholar 

  80. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.

    PubMed  Google Scholar 

  81. Bracarda S, Gernone A, Gasparro D, Marchetti P, Gianni L, Bortolus R, et al. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol. 2013.

  82. Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547–52.

    CAS  PubMed  Google Scholar 

  83. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002;84(3):378–82.

    CAS  PubMed  Google Scholar 

  84. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994;53(1):121–2.

    CAS  PubMed  Google Scholar 

  85. Elligers KT, Davies M, Sanchis D, Ferencz T, Saif MW. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? JOP J Pancreas. 2008;9(2):197–202.

    Google Scholar 

  86. Enrique E, Malek T, Castello JV, de Mateo JA. Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2008;100(1):86.

    Google Scholar 

  87. Syrigou E, Makrilia N, Vassias A, Nikolaidis I, Xyla V, Manolopoulos L, et al. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? Anti-Cancer Drugs. 2010;21(3):333–8.

    CAS  PubMed  Google Scholar 

  88. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45–51.

    CAS  PubMed  Google Scholar 

  89. Limsuwan T, Castells MC. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf. 2010;9(1):39–53.

    CAS  PubMed  Google Scholar 

  90. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs—an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702–12.

    CAS  PubMed  Google Scholar 

  91. Prieto Garcia A, Pineda de la Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol. 2010;20(2):170–1.

    CAS  PubMed  Google Scholar 

  92. Messaad D, Sablayrolles P, Pujol JL, Demoly P. Successful docetaxel tolerance induction. Allergy. 2003;58(12):1320–1.

    CAS  PubMed  Google Scholar 

  93. Zambonino MA, Corzo JL, Munoz C, Requena G, Ariza A, Mayorga C, et al. Diagnostic evaluation of hypersensitivity reactions to beta-lactam antibiotics in a large population of children. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2014;25(1):80–7.

    Google Scholar 

  94. Garcia Nunez I, Barasona Villarejo MJ, Algaba Marmol MA, Moreno Aguilar C, Guerra Pasadas F. Diagnosis of patients with immediate hypersensitivity to beta-lactams using retest. J Investig Allergol Clin Immunol. 2012;22(1):41–7.

    CAS  PubMed  Google Scholar 

  95. Silva R, Cruz L, Botelho C, Castro E, Cadinha S, Castel-Branco MG, et al. Immediate hypersensitivity to penicillins with negative skin tests—the value of specific IgE. Eur Ann Allergy Clin Immunol. 2009;41(4):117–9.

    CAS  PubMed  Google Scholar 

  96. Fernandez J, Torres MJ, Campos J, Arribas-Poves F, Blanca M, Group DA-D. Prospective, multicenter clinical trial to validate new products for skin tests in the diagnosis of allergy to penicillin. J Investig Allergol Clin Immunol. 2013;23(6):398–408.

    CAS  PubMed  Google Scholar 

  97. Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, Torres MJ, Blanca M, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy. 2007;62(1):47–52.

    CAS  PubMed  Google Scholar 

  98. Cromwell O, Pepys J, Parish WE, Hughes EG. Specific IgE antibodies to platinum salts in sensitized workers. Clin Allergy. 1979;9(2):109–17.

    CAS  PubMed  Google Scholar 

  99. Vanhaelen M, Duchateau J, Vanhaelen-Fastre R, Jaziri M. Taxanes in Taxus baccata pollen: cardiotoxicity and/or allergenicity? Planta Med. 2002;68(1):36–40.

    CAS  PubMed  Google Scholar 

  100. Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG, Emergency Department Anaphylaxis Investigators. Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol. 2009;124(4):786–92 e4.

    CAS  PubMed  Google Scholar 

  101. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371–6.

    PubMed  Google Scholar 

  102. Brown SG, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australasia EMA. 2004;16(2):120–4.

    Google Scholar 

  103. Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, et al. Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013;132(5):1141–9 e5.

    CAS  PubMed  Google Scholar 

  104. Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther. 2013;35(5):548–62.

    CAS  PubMed  Google Scholar 

  105. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–25.

    PubMed Central  PubMed  Google Scholar 

  106. Abajian M, Mlynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep. 2012;12(4):281–7.

    PubMed  Google Scholar 

  107. Medic N, Desai A, Komarow H, Burch LH, Bandara G, Beaven MA, et al. Examination of the role of TRPM8 in human mast cell activation and its relevance to the etiology of cold-induced urticaria. Cell Calcium. 2011;50(5):473–80.

    CAS  PubMed Central  PubMed  Google Scholar 

  108. Douaiher J, Succar J, Lancerotto L, Gurish MF, Orgill DP, Hamilton MJ, et al. Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing. Adv Immunol. 2014;122:211–52.

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol. 2005;5(4):359–64.

    PubMed  Google Scholar 

  110. Sala-Cunill A, Cardona V, Labrador-Horrillo M, Luengo O, Esteso O, Garriga T, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. Int Arch Allergy Immunol. 2013;160(2):192–9.

    PubMed  Google Scholar 

  111. Cardet JC, Castells MC, Hamilton MJ. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep. 2013;13(1):10–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  112. Hamilton RG. Clinical laboratory assessment of immediate-type hypersensitivity. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S284–96.

    PubMed  Google Scholar 

  113. Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia. 2004;59(7):695–703.

    CAS  PubMed  Google Scholar 

  114. Michalska-Krzanowska G. Tryptase in diagnosing adverse suspected anaphylactic reaction. Adv Clin Exp Med Off Organ Wroclaw Med Univ. 2012;21(3):403–8.

    Google Scholar 

  115. Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989;83(5):1551–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  116. Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J Allergy Clin Immunol. 2013;131(1):144–9.

    CAS  PubMed  Google Scholar 

  117. Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs. 2004;15(6):581–5.

    CAS  PubMed  Google Scholar 

  118. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96(3):824–9.

    CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Joana Caiado declares that she has received grant money from Fundação Luso-Americana para o Desenvolvimento (FLAD). Matthieu Picard declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Avenida Professor Egas Moniz, 1649-035, Lisbon, Portugal

    Joana Caiado

  2. Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 1 Jimmy Fund Way, Smith Building, Boston, MA, 02115, USA

    Joana Caiado & Matthieu Picard

Authors
  1. Joana Caiado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthieu Picard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joana Caiado.

Additional information

This article is part of the Topical Collection on Anaphylaxis and Drug Allergy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Caiado, J., Picard, M. Diagnostic Tools for Hypersensitivity to Platinum Drugs and Taxanes: Skin Testing, Specific IgE, and Mast Cell/Basophil Mediators. Curr Allergy Asthma Rep 14, 451 (2014). https://doi.org/10.1007/s11882-014-0451-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-014-0451-7

Keywords

Search

Navigation